Summit Therapeutics (MEX:SMMT) Current Accrued Expense: MXN1,135.15 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

MEX:SMMT Summit Therapeutics Inc MEX:SMMT
30 GF Score
Price MXN290.12
! 2 Warning Signs
View Full Analysis

What is Summit Therapeutics Current Accrued Expense?

Summit Therapeutics MEX:SMMT 30 Current Accrued Expense is MXN1,135.15 Mil as of Jun. 2026. GuruFocus rates MEX:SMMT with a GF Score™ of 30/100. The stock has 2 warning signs investors should review.

Summit Therapeutics's Current Accrued Expense for the quarter that ended in Jun. 2026 was MXN1,135.15 Mil.

Summit Therapeutics's quarterly Current Accrued Expense increased from Dec. 2025 (MXN577.98 Mil) to Mar. 2026 (MXN799.16 Mil) and increased from Mar. 2026 (MXN799.16 Mil) to Jun. 2026 (MXN1,135.15 Mil).

Summit Therapeutics's annual Current Accrued Expense increased from Dec. 2023 (MXN149.09 Mil) to Dec. 2024 (MXN407.81 Mil) and increased from Dec. 2024 (MXN407.81 Mil) to Dec. 2025 (MXN577.98 Mil).

Summit Therapeutics Current Accrued Expense Related Terms

Summit Therapeutics Current Accrued Expense Historical Data

* Premium members only.

The historical data trend for Summit Therapeutics's Current Accrued Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Summit Therapeutics Current Accrued Expense Chart

Summit Therapeutics Annual Data
Trend Jan16 Jan17 Jan18 Jan19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Current Accrued Expense
Get a 7-Day Free Trial Premium Member Only Premium Member Only 147.64 207.91 149.09 407.81 577.98

Summit Therapeutics Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Current Accrued Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 492.35 496.06 577.98 799.16 1,135.15
MEX:SMMT
30GF Score
Summit Therapeutics Inc MEX:SMMT
Current Accrued Expense is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Summit Therapeutics Current Accrued Expense Calculation

Current Accrued Expense is the expense incurred during the accounting period, but not required to be paid until a later date. It includes compensation, interest, pensions and all other miscellaneous accruals reported by the company.

What does a Current Accrued Expense of MXN1,135.15 Mil mean?
Summit Therapeutics (MEX:SMMT) has a Current Accrued Expense of MXN1,135.15 Mil as of Jun. 2026. Current Accrued Expense records the total amount of accrued expenses. View historical data on Summit Therapeutics and its competitors.
Is Summit Therapeutics' Current Accrued Expense too high?
Summit Therapeutics' current Current Accrued Expense is MXN1,135.15 Mil. Overall, Summit Therapeutics has a GF Score™ of 30/100, reflecting its overall financial health beyond just this single metric.
How does Summit Therapeutics' Current Accrued Expense compare to TECH and AXSM?
Summit Therapeutics' Current Accrued Expense of MXN1,135.15 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Current Accrued Expense for a Biotechnology company?
A good Current Accrued Expense depends on the Biotechnology industry context. However, Current Accrued Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Current Accrued Expense mean?
A high Current Accrued Expense can signal that a stock is expensive relative to its fundamentals. Current Accrued Expense records the total amount of accrued expenses. View historical data on Summit Therapeutics and its competitors. Summit Therapeutics's current Current Accrued Expense is MXN1,135.15 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Summit Therapeutics stock overvalued right now?
Summit Therapeutics (MEX:SMMT) has a current Current Accrued Expense of MXN1,135.15 Mil. The current Current Accrued Expense is MXN1,135.15 Mil. Summit Therapeutics' overall GF Score™ is 30/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Current Accrued Expense calculated?
Current Accrued Expense is calculated from a company's financial statements. For Summit Therapeutics (MEX:SMMT), the current Current Accrued Expense is MXN1,135.15 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Summit Therapeutics Business Description

Other Exchanges SMMT:USA
Address 601 Brickell Key Drive, Suite 1000, Miami, FL, USA, 33131
Summit Therapeutics Inc is a biopharmaceutical company that focuses on the discovery, development, and commercialization of novel antibiotics for serious infectious diseases. Its CDI (Clostridiodes difficile infection) product candidate is ridinilazole, an orally administered small molecule antibiotic. It has two geographical segments: the United States and the United Kingdom.
30GF Score

Get the complete analysis for MEX:SMMT

Current Accrued Expense is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

MXN290.12
Price